AB Science présenter
AB Science présentera les résultats de son étude de phase 3 dans l’asthme sévère au Congrès Annuel International de European Respiratory Society
September 08, 2020 02:44 ET | AB Science
Paris, 8 septembre 2020, 7h30 AB Science présentera les résultats de son étude de phase 3 dans l’asthmesévère au Congrès Annuel International de European Respiratory Society  ...
AB Science to presen
AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress
September 08, 2020 02:44 ET | AB Science
Paris, 08 September 2020, 7.30am AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congress Abstract...
Equillium_Square_Logo.png
Equillium to Present at BTIG Virtual Biotechnology Conference 2020
July 30, 2020 16:07 ET | Equillium
LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium to Present at Jefferies Virtual Healthcare Conference
May 21, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium Reports First Quarter 2020 Financial Results
May 13, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_Square_Logo.png
Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 07, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Lettre aux partenair
Lettre aux partenaires d'AB Science concernant l’impact de la pandémie COVID-19 sur les études cliniques d’AB Science
April 07, 2020 12:33 ET | AB Science
Paris, 7 avril 2020, 18h15 Lettre à nos partenaires concernant l’impact de la pandémie COVID-19 sur lesétudes cliniques d’AB Science     Chers partenaires, À l'heure actuelle, nous prévoyons que...
Letter to AB Science
Letter to AB Science stakeholders on COVID-19 pandemic impact on AB Science clinical studies
April 07, 2020 12:33 ET | AB Science
Paris, April 07, 2020, 6.15pm A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies Dear Stakeholders, At this time, we expect that the COVID-19 pandemic will have...
Equillium_Square_Logo.png
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
March 26, 2020 16:07 ET | Equillium
EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020 LA JOLLA, Calif., March ...
Equillium_Square_Logo.png
Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
February 13, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...